Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease. (15th October 2020)

• Record Type: Journal Article
• Authors: Naz, Falaq; Rahul, ; Fatima, Mahino; Naseem, Swaleha; Khan, Wasi; Mondal, Amal Chandra; Siddique, Yasir Hasan
• Is Part Of: Neuropharmacology. Volume 177(2020)
• Publication Date: 2020-10-15
• Subjects: Parkinson's disease (PD) -- Ropinirole -- Drosophila -- Nanocomposite -- Dopamine agonist; Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2020.108216
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disease due to the degeneration of dopaminergic neurons in substantia nigra pars compacta of the mid brain. The present study investigates the neuro-protective role of synthesized ropinirole silver nanocomposite (RPAgNC) in Drosophila model of PD. α-synuclein accumulation in the brain of flies (PD flies) leads to the damage of dopaminergic neurons, dopamine depletion, impaired muscular coordination, memory decline and increase in oxidative stress. Ingestion of the RPAgNC by Drosophila significantly prevented the neuronal degeneration compared to only ropinirole. The results confirm that the RPAgNC exerts more neuro-protective effect compared to dopamine agonist i.e. ropinirole as such drug in experimental PD flies. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'. Highlights: RPAgNC was synthesized and characterized. RPAgNC was more effective compared to Ropinirole. By creating nanocomposites the side effects of the drug can be reduced.